Cargando…
Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129921/ https://www.ncbi.nlm.nih.gov/pubmed/37004641 http://dx.doi.org/10.1007/s12325-023-02491-4 |
| _version_ | 1785030860807864320 |
|---|---|
| author | Marshall, Jonathan Sharma, Akanksha Darken, Patrick Ouwens, Mario Singh, Barinder Tansey-Dwyer, Deniz |
| author_facet | Marshall, Jonathan Sharma, Akanksha Darken, Patrick Ouwens, Mario Singh, Barinder Tansey-Dwyer, Deniz |
| author_sort | Marshall, Jonathan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10129921 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Healthcare |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101299212023-04-27 Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” Marshall, Jonathan Sharma, Akanksha Darken, Patrick Ouwens, Mario Singh, Barinder Tansey-Dwyer, Deniz Adv Ther Letter Springer Healthcare 2023-04-01 2023 /pmc/articles/PMC10129921/ /pubmed/37004641 http://dx.doi.org/10.1007/s12325-023-02491-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Marshall, Jonathan Sharma, Akanksha Darken, Patrick Ouwens, Mario Singh, Barinder Tansey-Dwyer, Deniz Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title | Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title_full | Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title_fullStr | Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title_full_unstemmed | Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title_short | Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis” |
| title_sort | letter to the editor regarding “fluticasone furoate/umeclidinium/vilanterol (ff/umec/vi) triple therapy compared with other therapies for the treatment of copd: a network meta-analysis” |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129921/ https://www.ncbi.nlm.nih.gov/pubmed/37004641 http://dx.doi.org/10.1007/s12325-023-02491-4 |
| work_keys_str_mv | AT marshalljonathan lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis AT sharmaakanksha lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis AT darkenpatrick lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis AT ouwensmario lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis AT singhbarinder lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis AT tanseydwyerdeniz lettertotheeditorregardingfluticasonefuroateumeclidiniumvilanterolffumecvitripletherapycomparedwithothertherapiesforthetreatmentofcopdanetworkmetaanalysis |